Posted in | News | Nanomedicine | Microscopy

Innovative Hand-Held Tool and App to Monitor for Signs of Skin Cancer Unveiled at World Dermatology Conference

Simon Fraser University PhD alumna Maryam Sadeghi is unveiling MoleScope™, an innovative hand-held tool that uses a smartphone to monitor skin for signs of cancer, at the World Congress of Dermatology conference in Vancouver June 9-13.

Maryam Sadeghi shows off an early version of MoleScope™, an innovative tool and app for electronic devices like smartphones and iPads. Users can monitor their moles for signs of skin cancer.

Sadeghi, who laid the groundwork for the device during her PhD thesis research, has spent three years transitioning from academic research to her start-up venture, MetaOptima Technology Inc.

The company’s inaugural product is MoleScope™, a device that enables people to monitor their moles and skin health, share images with family and healthcare providers and eventually, connect with skin specialists online.

“I love working with people to help them manage their health,” says Sadeghi. “This is exactly what I imagined doing as a student and now my vision is being realized through the launch of MoleScope™, and my company, MetaOptima Technology.”

MoleScope™ comprises a mini-microscope that attaches to a smartphone, an app (iOS, Android, or web compatible) and a cloud-based analytical platform called DermEngine™. Once people take high-quality, high-resolution images of suspicious moles or skin abnormalities, they can archive images and communicate concerns with others.

MoleScope™ is expected to provide healthcare benefits in communities without access to medical specialists and in those with long waitlists, as people can self-monitor their moles and track changes over time.

Visual changes in skin often signal the possibility of skin cancer. It’s estimated that 70 per cent of skin cancer is caught by individuals and family members.

The company has developed two versions of the product:  a consumer version expected to retail at $149; and a more expensive professional version to be presented at the World Congress of Dermatology meeting.

MoleScope™ has received approval from Health Canada, and is FDA- registered as a Class 1 medical device in the U.S. A CE mark in the EU and TGA approval in Australia is expected shortly. The company is initiating an early adopter program with qualified dermatologists and receiving strong interest from potential distributors and channel partners throughout the world.

Sadeghi is CEO of MetaOptima Technology and the company has grown to nine full-time employees. MetaOptima grew out of the SFU Innovation Office’s Venture Connection program and Sadeghi’s former mentor in the program, Hugh MacNaught, is now chair of the company’s board of directors.

“It was obvious from the outset that Maryam had identified an unmet medical need and that she had strong insights in the application of technology to address that need,” says MacNaught. “It has been a pleasure to watch her rally people around her vision and to work tirelessly to make it a reality.”

Sadeghi won recognition during the research and development phase of MoleScope™, winning WaveFront’s Wireless Prize package ($40,000) in the BCIC-New Ventures Competition in 2013, plus a prize in the Plug & Play Silicon Valley competition in Vancouver in July 2014.

While a graduate student at SFU (she earned a PhD in computing science in 2012 under supervisor and professor emeritus Stella Atkins) Sadeghi and her team also developed the UV Canada app for skin cancer awareness and prevention. It was released in June 2011 and donated to the BC Cancer Agency at Vancouver General Hospital.

Sadeghi’s PhD research on skin cancer prevention and analyzing dermoscopic images for early skin cancer diagnosis using intelligent computer technologies was recognized with a 2012 Innovation Challenge Award from the Natural Sciences and Engineering Research Council of Canada.

Source: http://www.sfu.ca/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.